本报讯 （记者张敏）2月23日，港股生物医药上市企业MirxesHolding Company Limited（以下简称"觅 瑞"）发布自愿性公告，宣布其结直肠癌早筛前瞻性临床研究CADENCE CRC已完成全部入组。觅瑞表 示，完成入组标志着实现关键里程碑，研究将进入后期实验室分析与数据评估阶段。该公司预期在完成 数据分析及随访后于2026年内公布主要研究结果。 持续夯实早筛产品管线 miRNA技术构筑壁垒 全球早筛赛道竞争激烈，觅瑞凭借独有miRNA核心技术平台，突破传统检测局限，走出差异化路径， 不仅成为亚洲早筛标杆，更跻身全球少数实现该技术商业化的企业，技术壁垒显著。其自主研发的 mSMRT-qPCR技术，性价比优势较高通量测序尤为突出。 不同于海外企业聚焦欧美，觅瑞精准锚定东盟+中国核心市场，直击区域早筛需求空白。亚洲是全球癌 症负担最重的地区之一，但受检测可及性、人群接受度、医疗资源分布制约，早筛覆盖率长期偏低。觅 瑞深耕本土，通过本土化临床研究、贴合市场的商业化布局及与当地机构深度合作，构建起覆盖亚洲的 临床与商业化网络。 2023年启动的CADENCE CRC研究，是觅瑞肠癌早筛的核心布局，该 ...

Group 1 - The core viewpoint of the articles highlights that Meinian Health (002044.SZ) is leveraging AI technology to enhance its revenue streams, with projected revenue for the first half of 2025 estimated between 3.96 billion to 4.2 billion yuan, and AI-related revenue exceeding 140 million yuan, reflecting a year-on-year growth of 62.36% [1][2] - The company is actively promoting the conversion from group health checks to individual health checks, aiming to enhance customer retention and increase repurchase rates through strategies like "full journey customer operation" and "private domain transformation" [2] - Meinian Health has entered a strategic partnership with Alibaba's Damo Academy to implement AI technology for multi-cancer screening, which is expected to improve screening efficiency and expand early detection capabilities for asymptomatic populations [2][3] Group 2 - The company is transitioning from a traditional health check service provider to an AI-driven health management solution platform, with significant potential for future platform value as health data becomes increasingly valuable [3] - Efforts to optimize client acquisition strategies and enhance service quality are ongoing, with a focus on maximizing operational efficiency and innovation in revenue generation [1][2]